BroadOak Capital Partners Adds More Than $200 Million of Permanent Capital to Supplement Investment Platform
Evergreen capital base enables BroadOak to pursue its life sciences growth capital strategy over a longer horizon of investment cycles and to be opportunistic in special situations. BETHESDA, Md.–(BUSINESS WIRE)–BroadOak Capital Partners (“BroadOak”), a life science focused investment and advisory firm, announced it has added over $200 million of permanent capital to its investing platform, […]
Pluristyx Completes Investment Round to Expand Product Portfolio and Commercial Operations
We’re pleased to share that Pluristyx, a BroadOak Capital Partners portfolio company, has recently completed an investment round to expand inventory with new clinical grade cell lines. This strategic investment will enable Pluristyx to be the industry leader offering the highest quality stem cells available anywhere. The full press release is below. Seattle, Washington: July […]
Particle Dynamics acquires EuroAPI UK
We’re pleased to share that Particle Dynamics, a BroadOak Capital Partners portfolio company, has acquired EuroAPI UK Ltd., a commercial spray drying facility in Haverhill, UK. This acquisition expands Particle Dynamics’ global GMP-compliant manufacturing capacity and strengthens their position as a leading CDMO to meet growing demand for improved bioavailability, solubility and stability of therapeutic […]
PAK BioSolutions Raises $12 Million Series A to Expand Continuous Biomanufacturing Product Line
BroadOak Capital Partners invested in PAK Biosolutions to expand their commercial and product development. The full press release is below. Vienna, VA: Today, PAK BioSolutions announced that it has raised $12M from Arboretum Ventures, BroadOak Capital Partners, and other investors to expand commercial and product development efforts for its line of automated continuous manufacturing systems […]
Pluristyx Closes Major Fundraising Round
BroadOak Capital Partners led Pluristyx’s latest fundraising round, which featured participation from existing investors and key opinion leaders in the life sciences sector. The full press release is below. SEATTLE, WA – December 21, 2023 – Pluristyx, a leading provider of tools, technologies and services for the development of cell therapies, has today announced the closing […]
celares GmbH Sells to Biosynth
BroadOak Capital Partners advised Biosynth on the acquisition of celares GmbH. Celares provides customized bioconjugation solutions for Pharma and IVD industries. The full press release is below. Staad, 11th July 2023 – Biosynth, a supplier of critical raw materials to the life science industry, is pleased to announce today that it has acquired celares, a leader […]
Genomenon Acquires Boston Genetics
Genomenon, a BroadOak portfolio company and a leader in genomic intelligence, acquired Boston Genetics, a genomics interpretation and curation company. The full press release is below. Genomenon Inc., a leader in Genomic Intelligence, today announced it has acquired Boston Genetics, a genomics interpretation and curation company. By combining Genomenon’s unrivaled AI-powered platform for genomic knowledge […]
Indee Labs Investment from BroadOak BioTools Venture Fund
BroadOak Capital Partners invested in Indee Labs out of its BioTools Venture Fund to support the development of Hydropore, which enables modified immune cell research and development with improved yield and function using a simple workflow, commercial GMP-grade buffers and a small footprint. DeciBio Consulting, a boutique life science strategy consulting firm, partnered with BroadOak […]
Sanguine Biosciences Partners with BroadOak
Sanguine is a leader in custom specimen procurement used by biopharmaceutical companies to accelerate precision medicine and cell & gene therapy R&D. Our investment will help Sanguine expand laboratory operations, leukapheresis offerings, and their patient donor network. The full press release is below. WALTHAM, Mass., Jan. 9, 2023 /PRNewswire/ — Sanguine Biosciences (“Sanguine”), a leader […]
BroadOak Invests in CDI Laboratories
BroadOak invested in CDI Labs, a provider of serological biomarker discovery services and monoclonal antibody manufacturing and validation services, to expand and scale antibody biomarker discovery platforms. The full press release is below. BALTIMORE, Jan. 9, 2023 /PRNewswire/ — CDI Laboratories, Inc (“CDI Labs”) announced today that it has received a significant investment from BroadOak Capital Partners (“BroadOak”) […]